To include your compound in the COVID-19 Resource Center, submit it here.

EpiCept NP-1: Interim Phase IIb data

Interim data from 370 evaluable patients in a double-blind Phase IIb

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE